Novartis’ Kisqali Could Challenge Pfizer’s Ibrance After Phase II First-Line Aggressive Breast Cancer Success

The Swiss major’s CDK4/6 inhibitor has met the primary endpoint in a Phase II trial in first-line aggressive advanced breast cancer, supporting off-label use as the firm goes head to head with Pfizer’s rival drug Ibrance.